OncoMatch/Clinical Trials/NCT05970666
Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
Is NCT05970666 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies TACE with adebrelimab and bevacizumab for adebrelimab.
Treatment: TACE with adebrelimab and bevacizumab — To evaluate the efficacy and safety of TACE combined with adebrelimab and bevacizumab transformation in unresectable hepatocellular carcinoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage ⅡA, ⅡB, ⅢA, ⅢB (CNLC)
The CNLC stage is Ⅱa-Ⅲb stage
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: targeted therapy
have received targeted therapy and other PD-1 / PD-L1 inhibitor therapy
Cannot have received: PD-1/PD-L1 inhibitor
have received targeted therapy and other PD-1 / PD-L1 inhibitor therapy
Cannot have received: systemic therapy
Received major surgery or chemotherapy or other systemic therapy for target lesions (including not limited to radiation therapy, ablation therapy, etc.) within 1 month prior to enrollment
Lab requirements
Blood counts
Hemoglobin ≥90g/L; WBC ≥3x10^9/L; ANC ≥1.5x10^9/L; Platelet ≥80x10^9/L
Kidney function
Serum creatinine ≤1.5x ULN
Liver function
Child-Pugh grade A or B (5-7 points); Bilirubin <1.5x ULN; ALT and AST <5x ULN
Cardiac function
No severe cardiovascular disease; LVEF ≥50%; no poorly controlled arrhythmia (QTc <450 ms men, <470 ms women)
The Child-Pugh grade of liver function is A grade or B grade (5-7 points); Bilirubin (BIL) <1.5 times the upper limit of normal value (ULN); Glutamic gamma aminotransferase (ALT) and glutamate aminotransferase AST <5 ULN; Serum creatinine (Cr)≤1.5ULN; Hemoglobin (HB), 90g / L, White blood cell count (WBC) 3109 / L Absolute neutrophil count (ANC) 1.5109 / L, Platelet (PLT) 80109 / L; Previous severe cardiovascular disease, including but not limited to the following diseases: myocardial ischemia or myocardial infarction, poorly controlled arrhythmia (including 450 ms in QTc men and 470 ms in women); cardiac dysfunction by NYHA, or cardiac ultrasound indicating left ventricular ejection fraction (LVEF) <50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05970666 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage ⅡA or ⅡB or ⅢA or ⅢB is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages